Shenzhen TargetRx, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Dec 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 8, 2027The maintenance fee for Benzenesulfonylbenazamide compound for inhibiting BCL-2 protein and composition and use thereof (US 11,718,611) comes due Feb 8, 2027. Unpaid by Aug 9, 2027, it lapses early.
- 1 fee due Mar 5, 2027The maintenance fee for Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity (US 11,746,110) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
- 1 fee due Apr 30, 2027The maintenance fee for Substituted Pyrazole Compounds, Compositions Containing Same, and Use Thereof (US 11,802,113) comes due Apr 30, 2027. Unpaid by Nov 1, 2027, it lapses early.
- 1 fee due May 19, 2027The maintenance fee for Substituted heteroaryl compound, composition containing same, and application thereof (US 10,479,767) comes due May 19, 2027. Unpaid by Nov 19, 2027, it lapses early.
- 2 fees due Jun 12 to 30, 2027 · next Jun 12
- 1 fee due Jul 28, 2027The maintenance fee for Macrocycle and Composition Comprising Thereof (US 10,543,199) comes due Jul 28, 2027. Unpaid by Jan 28, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,479,767 | Substituted heteroaryl compound, composition containing same, and application thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,851,062 | Substituted heteroaryl compound, composition containing same, and application thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,519,193 | Steroidal compound, composition containing the same and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,543,199 | Macrocycle and Composition Comprising Thereof In force · High confidence | In force | High confidence | |
| US 10,780,082 | Macrocycle and Composition Comprising Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,995,103 | Substituted boric acid compound, pharmaceutical composition comprising same, and application thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,111,233 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity In force · From the USPTO record | In force | From the USPTO record | |
| US 11,517,561 | Macrocycle and Composition Comprising Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,875,853 | (Hetero)arylamide compound for inhibiting protein kinase activity In force · From the USPTO record | In force | From the USPTO record | |
| US 11,091,462 | (Hetero)arylamide compound for inhibiting protein kinase activity In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 3 no status recorded